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Erythema multiforme (EM) is an immune-
mediated reaction first described by von Hebra1 in
1860, presenting typically as acrofacial target lesions.
The rash may be confined to the skin (EM minor), or
it may involve ocular, oral, or genital mucosa with
systemic symptoms (EMmajor). In most cases, only 1
outbreak of EM occurs in a lifetime; however, very
rarely, repeated episodes of EMmay occur, known as
recurrent EM.2 Few cases of pediatric recurrent EM
have been reported, with the etiology being identi-
fied in less than half of these cases.3 We report a
pediatric case of recurrent EM resistant to conven-
tional treatments in which a peculiar human leuko-
cyte antigen (HLA) haplotype has been identified.CASE REPORT
An 8-year-old boy presented to the pediatric
emergency room for the abrupt onset of erythema-
tous patches with central vesicles localized to the
upper and lower limbs, including the palmo-plantar
regions. The lesions appeared a few days after the
spontaneous resolution of a herpetic gingivostoma-
titis. The patient had no drug history and was
otherwise healthy. His personal history included a
previous EM minor episode after herpetic stomatitis,
which occurred 1 year prior. He was discharged withDepartment of Internal Medicine and Medical Spe-
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acyclovir therapy. Three days after discharge, the
patient came back to the emergency room because
of the onset of extensive de-epithelialization of the
oral mucosa, tongue, and lips (Fig 1, A); ocular
hyperemia associated with photophobia; genital
erosions; and symmetrical blisters and ulcerations
involving the upper and lower limbs (Fig 1 B and C )
and the trunk. He had also fever, malaise, and
myalgia. Herpes simplex virus (HSV) 1 serology
found a positivity of IgM and IgG; cytomegalovirus,
parvovirus B19, and Rickettsia and Mycoplasma
pneumoniae serology (both IgM and IgG) were
negative.
Two skin biopsies performed on his left leg found
epidermal spongiosis, keratinocytes apoptosis with
blistering at the dermoepidermal junction, and poor
dermal inflammatory infiltrate (Fig 2, A and B); direct
immunofluorescence was negative. The clinical
history, cutaneous lesions, serologic results andJAAD Case Reports 2019;5:617-20.
2352-5126
 2019 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
https://doi.org/10.1016/j.jdcr.2019.05.013
617
Fig 1. An 8-year-old boy presents with abrupt onset of extensive sero-heamatic crusts covering
his lips, associated with de-epithelialization of the oral mucosa and tongue (A). Blisters and
ulcerations with perilesional erythema are evident on the upper limbs including palmar regions
(B) and lower limbs (C).
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HSV-related EM major.4,5
Systemic treatment with methylprednisolone at a
dose of 1 mg/kg/d was started in association with
acyclovir at a dose of 10 mg/kg/d. In the following
days, a worsening with extension of de-
epithelialization areas was observed. Intravenous
immunoglobulin (IVIG) at a dose of 400 mg/kg/d
for 5 days was started. A rapid improvement of signs
and symptoms was observed, followed by complete
resolution of mucocutaneous involvement within a
week.
Because of the rapid disease progression with
major extensive mucous membrane involvement,
we performed HLA haplotype analysis to determine
whether particular major histocompatibility complex
alleles would predispose to this recurrent HSV-
induced, severe EM. The presence of the HLA-
B*5801 genotype was discovered. At a 3-month
follow-up visit, the patient had maintained complete
clinical resolution continuing to take acyclovir
400 mg/d to prevent herpetic recurrences.
DISCUSSION
EM is an acute inflammatory disease presenting
with annular erythematous plaques or urticarial
papules that may evolve in typical target lesions,
mainly involving acral sites.6 It occurs morefrequently in young adults; however, a few pediatric
cases have been reported in the literature.2 Several
etiologies have been associated with EM (eg, drugs,
autoimmune disorders, malignancy, radiation); in-
fectious processes are, however, the most common
triggers, encompassing approximately 90% of cases.
HSV is estimated to be involved in about 70% of cases
of EM; M pneumoniae is also a prominent
pathogen.7,8
In our patient, the close temporal relation be-
tween the onset of EM minor with a rapid worsening
in EM major and its close relationship with recur-
rence of herpetic gingivostomatitis is highly sugges-
tive for a causal role of HSV infection. Relapse of EM
coinciding with HSV 1 or 2 infection relapses has
been widely reported in the literature; the link
between HSV and EM is probably caused by an
autoimmune cross-reactivity mechanism, as a high
number of peptides is shared between the HSV and
human proteins.9
Prompt hydration, pain control, accurate skin
care, and early identification and management of
potential triggers are the mainstay of EM major
treatment.5 Although IVIG and systemic corticoste-
roids are the main therapy options, their effective-
ness is still debated.2,3 In our case, we observed a
rapid improvement progress into a lasting resolution
of the condition after the introduction of IVIG
Fig 2. Biopsy performed from perilesional skin of left leg
is characterized by blistering at the dermoepidermal
junction (black arrows), epidermal spongiosis, and kera-
tinocytes apoptosis (red arrows). (A and B, Hematoxylin-
eosin stain; original magnifications: A, 320; B, 340.)
JAAD CASE REPORTS
VOLUME 5, NUMBER 7
Grassi et al 619therapy. The efficacy of IVIGs depends essentially on
their ability to interfere with ligand-induced kerati-
nocytes apoptosis.10
Prognosis of EM major mainly depends on the
extent of skin and mucosal involvement2 and on a
prompt treatment. Increasing evidence suggests a
role of the immune system in the pathogenesis of EM
reactions, but little was known about the predispo-
sition to these reactions until recently.11-13
In our patient, because of the rapid disease
progression with major involvement of mucous
membranes, we performed HLA haplotype analysis
to determine whether particular major histocompat-
ibility complex alleles would predispose for this
recurrent HSV-induced severe EM.
Malo et al11 found that recurrent HSV-induced EM
is strongly associated with the rare HLA allele
DQB1*0402 in the disease form showing severe
mucous membrane involvement. Recently, Olsonet al12 performed a retrospective chart review for
cases of recurrent Stevens-Johnson syndrome in 9
children with mucous membraneepredominant
phenotype, and HLA-B51 was found in 3 patients;
HLA-B27 was found in 2 patients.
Furthermore, a strong association between some
genetic variants of HLA regions and the onset of
cutaneous hypersensitivity drug-related reactions
was also found. Recently, some drugs have been
identified as causing significant drug hypersensitivity
reactions in patients who have the specific HLA
alleles: abacavir and HLA-B*57:01, carbamazepine
and HLA-B*15:02/A*31:01, and allopurinol and HLA-
B*58:01.13-15
However, currently there is no information in the
literature about the role of the HLA-B*5801 haplo-
type in the developing of EM/Stevens-Johnson syn-
drome triggered by viral infections. As it is known,
immune response after HSV infection (in particular
HSV1) can trigger numerous different autoimmune
cross-reactions that depend mainly on the immuno-
logic history and HLA-associated genetic back-
ground of the patient.11,12,16 Therefore, we may
speculate that HLA-B*5801 haplotypes observed in
our patient may also be involved in the onset of HSV
infectionerelated recurrent EM.
The question as to whether these HLA alleles are
truly causative or acting as surrogate markers of
predisposition, however, is still unanswered, and
will require further investigations in larger patient
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